ArticleEuropean journal of neurology2025
Iatrogenic Cerebral Amyloid Angiopathy in Patients Treated With Cadaveric Dura Mater During Childhood Neurosurgery: A Retrospective Cohort Study.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Disease Progression in Iatrogenic Cerebral Amyloid Angiopathy.Neurology · 2026Article
- Severe Traumatic Brain Injury in Early Adulthood and Cerebral Amyloid Angiopathy: Still an Overlooked Association?Clinical case reports · 2026Article
- Prions and protein aggregates as pathogens, self-propagating structures, biomarkers, and therapeutic targets.Microbiology and molecular biology reviews : MMBR · 2025Review
- Iatrogenic cerebral proteinopathies-The dawn of transmissible neurodegeneration? The example of cerebral amyloid angiopathy.Frontiers in neurology · 2025Article
- Iatrogenic cerebral amyloid angiopathy: more cases to come.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIatrogenic cerebral amyloid angiopathy (iCAA) is a recently identified clinico-neuroradiological syndrome associated with medical procedures, particularly neurosurgical treatments involving cadaveric dura mater (e.g., Lyodura). iCAA can manifest as intracerebral hemorrhages, focal seizures, and cognitive impairment, with the risk following exposure currently unknown. We aim to evaluate the risk of developing iCAA in patients who underwent childhood neurosurgical treatment with Lyodura compared to those who did not.
methodsThis retrospective cohort study analyzed hospital records from the Christian-Doppler University Hospital in Salzburg, along with mortality data provided by the Austrian Federal Institute of Statistics (Statistik Austria). The study included all patients aged 0-18 who underwent neurosurgical procedures between January 1970 and January 1996. The primary endpoint was the diagnosis of iCAA and iCAA-related death.
resultsOf 569 pediatric neurosurgical patients, 388 (68%) were further analyzed. Four patients (1%) were diagnosed with probable iCAA at a median age of 42 years (IQR 40-47), with a median latency from surgery to symptom onset of 38 years (IQR 36-41). Only Lyodura recipients developed iCAA, with an incidence rate of 12% (OR 56, 95% CI: 6-2667). The overall incidence of symptomatic iCAA among recipients of any dura material was 5% (OR 19, 95% CI: 2-903).
conclusionsCadaveric dura mater, especially Lyodura, poses a long-term risk for developing iCAA. Further research is needed to determine susceptibility factors in Lyodura-exposed individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.